Advanced search
Publication Cover
Hematology Volume 26, 2021 - Issue 1
Submit an article Journal homepage
2,926
Views
2
CrossRef citations to date
0
Altmetric
Articles

Identification of hub genes with prognostic values in multiple myeloma by bioinformatics analysis

Jie Yanga Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People’s Republic of ChinaView further author information
,
Fei Wanga Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People’s Republic of ChinaView further author information
,
Shanliang Zhongb Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, People’s Republic of ChinaView further author information
&
Baoan Chena Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 453-459 | Published online: 24 Jun 2021

References

  • Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–527.
  • Lu J, Lee JH, Huang SY, et al. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. Br J Haematol. 2017;176(5):743–749.
  • Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543–556.
  • Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 2017;14(2):100-113.
  • Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955–2962.
  • Zhu FX, He YC, Zhang JY, et al. Using prognosis-related gene expression signature and connectivity Map for personalized drug repositioning in multiple myeloma. Med Sci Monit. 2019;25:3247–3255.
  • Viziteu E, Grandmougin C, Goldschmidt H, et al. Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer. 2016;114(5):519–523.
  • Bhaskar A, Tiwary BN. Hypoxia inducible factor-1 alpha and multiple myeloma. Int J Adv Res. 2016;4(1):706–715.
  • Ikeda S, Kitadate A, Abe F, et al. Hypoxia-inducible KDM3A addiction in multiple myeloma. Blood Adv. 2018;2(4):323–334.
  • Maiso P, Huynh D, Moschetta M, et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015;75(10):2071–2082.
  • Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5(10):588–599.
  • Long S, Long S, He H, et al. MicroRNA-765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6. Exp Ther Med. 2019;17(6):4741–4747.
  • Jin Z, Zhou S, Ye H, et al. The mechanism of SP1/p300 complex promotes proliferation of multiple myeloma cells through regulating IQGAP1 transcription. Biomed Pharmacother. 2019;119:109434.
  • Ikeda S, Kitadate A, Abe F, et al. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma. Cancer Sci. 2017;108(4):641–652.
  • Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
  • Ito K, Murphy D. Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol. 2013;2:79.
  • Walter W, Sanchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912–2914.
  • Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
  • Mizuno H, Kitada K, Nakai K, et al. Prognoscan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18.
  • Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109(4):1692–1700.
  • King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25(34):4675–4682.
  • Ha YS, Chihara Y, Yoon HY, et al. Downregulation of fumarate hydratase is related to tumorigenesis in sporadic renal cell cancer. Urol Int. 2013;90(2):233–239.
  • Sudarshan S, Shanmugasundaram K, Naylor SL, et al. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2alpha accumulation and promotes migration and invasion. PLoS One. 2011;6(6):e21037.
  • Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8(2):143–153.
  • Yang J, Kong P, Yang J, et al. High TSTA3 expression as a candidate biomarker for poor prognosis of patients With ESCC. Technol Cancer Res Treat. 2018;17:1533033818781405.
  • Sun Y, Liu X, Zhang Q, et al. Oncogenic potential of TSTA3 in breast cancer and its regulation by the tumor suppressors miR-125a-5p and miR-125b. Tumour Biol. 2016;37(4):4963–4972.
  • Renaud M, Praz V, Vieu E, et al. Gene duplication and neofunctionalization: POLR3G and POLR3GL. Genome Res. 2014;24(1):37–51.
  • Petrie JL, Swan C, Ingram RM, et al. Effects on prostate cancer cells of targeting RNA polymerase III. Nucleic Acids Res. 2019;47(8):3937–3956.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.